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Abstract
Malignant gliomas, with an average survival time of 16-19 months after initial diagnosis, account for one of the 
most lethal tumours overall. Current standards in patient care provide only unsatisfying strategies in diagnostic and 
treatment for high-grade gliomas. Here we describe metabolic phenomena in the choline and glycine network asso-
ciated with stem cell culture conditions in the classical glioma cell line U87. Using high-resolution proton magnetic 
resonance spectroscopy of cell culture metabolic extracts we compare the metabolic composition of U87 chronically 
propagated as adherent culture in medium supplemented with serum to serum-free neurosphere growth. We found 
that the switch to neurosphere growth, besides the increase of cells expressing the putative glioma stem cell marker 
CD133, modulated a number of intracellular metabolites including choline, creatine, glycine, and myo-inositol that 
have been previously reported as potential diagnostic markers in various tumours.
These findings highlight the critical influence of culture conditions on glioma cell metabolism, and therefore particu-
lar caution should be drawn to the use of in vitro system research in order to investigate cancer metabolism.
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Introduction
Glioblastoma (GBM) is the most common and 
lethal adult glial brain tumour, with a  mean over-
all survival of 16-19 months after primary diagnosis 
under the current standard-of-care treatment scheme 
[26]. Despite enormous research efforts towards ear-
ly diagnosis and more efficient treatment, the prog-
nosis of GBMs remains dismal.
The influence of culture conditions has been wi de-
ly investigated in the field of glioma research, suggest-
ing that neurosphere cultures, compared to adherent 
growth, more closely resemble the original patient’s 
tumour [29] showing high stem cell compartment [1] 
and therefore are more suitable for testing of novel 
therapeutic spectras approaches [30]. In this report 
we describe altered relative concentrations of the cho-
lines, creatine, myo-inositol, and glycine in the human 
GBM cell line U87 propagated under stem cell condi-
tions as compared to classical monolayer culture. Fur-
thermore, U87 neurospheres showed significant high-
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er levels of the putative GBM stem cell marker CD133 
as their serum-propagated counterparts. Detection 
and targeting of miss-regulated choline-, myo-inosi-
tol-, creatine-, and glycine-metabolism has been de s-
cribed to have potential utility in the diagnosis and 
treatment of malignant gliomas [2-4,13,16,19].
This is, to our knowledge, the hitherto first link 
of changes in those oncometabolites [4,25] to varia-
tions in cell culture conditions of glioma cells. Inter- 
spectral co-analysis of metabolite concentrations 
under the two propagation conditions identified 
reductions in ratios of phosphocholine to glycero-
phosphocholine (PC/GPC) and glycine to total cho-
line (Gly/tCho) but increases in the quotient of total 
choline to total creatine (tCho/tCre) and PC/tCre, as 
well as Gly/myo-inositol (Gly/myo). This work should 
draw the attention of the scientific community on 
possible in vitro artefacts and on the need for appro-
priate models most closely resembling the in vivo 
biology of investigated tumours.
Material and methods
Cell culture
U87 cell line was purchased from American Type 
Cell Culture bank (www.ATCC.com) and propagated 
either as adherent culture in Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies) contain-
ing 20% foetal calf serum or as neurospheres (stem 
cell culture) in DMEM/F12 (3 : 1, both Life Technolo-
gies) medium supplemented with B27 (Life Technol-
ogies), 20 ng/ml recombinant human basic fibroblast 
growth factor (bFGF, Peprotech), 20 ng/ml recombi-
nant human epidermal growth factor (EGF, Pepro-
tech), Anti-Anti (Life Technologies), and 5 μg/ml hep-
arin (Sigma-Aldrich), as described before [12]. Cells 
were passaged at least eight times in each culture 
condition before they were subjected to experimen-
tal analysis.
Cell line identity was confirmed by analysis of nine 
tandem repeats plus a  gender-determining marker, 
Amelogenin, using the StemElite kit (Promega, Sup-
porting Information File).
Metabolic extractions of in vitro 
cultures, proton nuclear magnetic 
resonance spectroscopy (1H-NMR) and 
metabolite quantification.
A minimum of 7 × 106 cells were collected for each 
extraction (each condition n = 3). A  methanol-chlo-
roform-water (1/1/1, v/v/v) dual phase cell lyses pro-
tocol was applied to extract water and lipid-soluble 
metabolites as described before [9]. In this study we 
only assessed content of the water-soluble extracts. 
The lyophilised water-soluble extracts were resolved 
in 20 mM phosphate buffer pH 7 (10% v/v D2O, Sig-
ma-Aldrich, MO, USA) supplemented with sodium 
(2,2-dimethyl-2-silapentane-5-sulfonate) (DSS; Euri-
so-top, internal NMR-standard, STD) for the scans at 
the Research Centre in Jülich (Germany), and in D2O 
containing 0.24* μmol 3-(trimethylsilyl) propio nic-
2,2,3,3,-d4 acid (Sigma-Aldrich, internal concentration 
standard, STD) at John Hopkins Hospital. The spectras 
were acquired at 25°C on a Bruker Avance 500 spec-
trometer operating at 11.7 T using a 5-mm HX inverse 
probe, as previously described [9], at the Depart-
ment of Radiology in the John Hopkins Hospital, and 
a  Bruker Avance III HD 600 spectrometer operating 
at 14.1 T using a 5-mm TXI-cryo-probe at the Institute 
of Complex Systems (ICS-6) in the Research Centre in 
Jülich (Germany). Water suppression was achieved by 
applying a pulse-sequence using excitation sculpting 
with gradients. The fully relaxed 1H-NMR data were 
processed, and the signal integrals listed below were 
measured using Mestrenova V10 software (Mestrelab). 
All metabolite concentrations were quantified through 
peak integration after standardised performed phase 
correction and baseline fitting. The respective con-
centration standard served as intra-spectral normal-
isation for each 1H-NMR spectra, and metabolite con-
centrations within the same spectra were co-analysed 
and presented as means plus SDs.
FACS-based assessment of CD133+ cell 
population
Cells were stained for cell surface antigen CD133 
(AC133-PE, #130-098-826, Miltenyi Biotec) accord-
ing to the manufacturer’s protocols, as described 
before [11]. AC133-antibody without a  fluorescent 
dye (AC133-pure, #130-090-422, Miltenyi Biotec) 
was used as control. Fluorescence activated cell sort- 
ing (FACS) was performed on an Accuri C6 cytome-
ter (BD Biosciences, Franklin Lakes, NJ) whereas for 
post-processing data analysis FlowJo v10 software 
(FlowJo, Tree Star Inc, Ashland, OR) was applied.
Cell apoptosis assays
Cultures were dissociated to single cell suspen-
sion and viable cells were quantified using the MUSE 
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Count & Viability Assay Kit (#MCH100102, Merck 
KGaA, Darmstadt on a Muse Cell Analyser [#0500-
3115, Merck KGaA]). Apoptotic cells were quantified 
using the AnnexinV & Dead Cell Kit (#MCH100105, 
Merck KGaA, Darmstadt, Germany) on the Muse Cell 
Analyser, according to the manufacturer’s protocol. 
A minimum of 2000 gated events were acquired.
Statistical evaluation
Statistical evaluation was performed using Stu-
dents t-test in Statistica (Statsoft, OK, USA) and pre-
sented as means plus respective standard deviations.
Results
Modification of the culture condition alters the 
relative concentration of choline, creatine glycine, 
and myo-inositol in U87 glioma cells.
High-resolution 1H-NMR spectra were obtained 
as described above, and a representative spectrum is 
shown in Figure 1A. The most prominent metabolites 
were annotated and quantified, including adenine 
(Ade), myo-inositol (myo), glycine (Gly), phospho-
choline (PC), glycerophosphocholine (GPC), free cho-
line (fCho), total choline (tCho = fCho + PC + GPC), 
total creatine (tCre), glutathione (GSH), glutamine 
(Gln), glutamate (Glu), N-acetylaspartylglutamate 
(NAAG), alanine (Ala), lactate (Lac), threonine (Thr), 
and valine/isoleucine (Val/Iso). Due to the previously 
described importance in glioma biology we focused 
our quantitative analysis on choline, creatine, gly-
cine, and myo-inositol ratios (Fig. 1B).
The switch to neurosphere media decreased the 
ratio of PC/GPC (40%) and significantly diminished 
the Gly/tCho concentration (70%). In contrast, we 
detected an increase in the ratios of Gly/myo (65%), 
tCho/tCre (300%), and PC/tCre (280%), reaching sta-
tistical significance for the latter two.
Neurosphere assay condition increases 
the expression of cell surface marker 
CD133
U87 culture in classical serum-containing growth 
medium expressed very low levels of CD133+ cells 
(about the amount of the negative control, 1% CD133+ 
cells on average, Fig. 1C). Following their transfer 
into stem cell conditions, the CD133– population was 
increased to 18.5% (p-value ≤ 0.001, Fig. 2A). Similar 
results of CD133+ U87 cells in free-floating culture 
conditions have been published previously [6,21].
U87 neurosphere cultures exhibit 
a higher fraction of apoptotic cells
We identified increased levels of apoptosis and 
cell death in cells propagated under neurosphere 
growth conditions compared to their adherent 
counterparts as assessed by AnnexinV/Propiodium 
iodide-based quantification (Fig. 2B).
Discussion
In this work we analysed the changes of U87 cell 
metabolism depending on whether a monolayer or 
3D in vitro propagation has been applied. Our study 
of this human glioma cell line confirms the accu-
mulation or preferential selection of CD133+ cells, 
a putative brain tumour stem cell marker [15], under 
prolonged stem cell culture conditions compared 
to propagation in serum-containing media. Recent 
studies addressing the effect of different culture con-
ditions in in vitro mouse models of GBM described 
the robust enhancement of stem cell marker expres-
sion and self-renewal capacity of cells transferred 
from adherent growth to spheroid culture [1]. More-
over, neurosphere cultures are suggested to more 
closely resemble the original patient’s tumour [29] 
and therefore are more suitable for testing novel 
therapeutic approaches [30].
Using high-resolution magnetic resonance spec-
troscopy (1H-NMR) in extracts of cells chronically 
propagated under serum-free neurosphere growth, 
we identified several alterations in metabolite con-
centrations with proposed diagnostic utility as a re-
sponse to changed growth stimuli.
Phosphocholine (PC), glycerophosphocholine (GPC), 
and free choline (fCho) all play an important role in 
the membrane phospholipid household that accom-
panies cell cycle progression [10]. Moreover, dysregu-
lated choline metabolism has already been proposed 
as an underlying molecular event during cancerous 
malformation in a  variety of cancers [7], including 
GBM [2]. Interestingly, we found that U87 glioma neu-
rospheres exhibit a reduced PC/GPC ratio, although it 
is not statistically significant. The PC/GPC ratio has 
been shown to be elevated in aggressive breast can-
cer cells [8], however, the diagnostic impact of this 
parameter in brain cancers has been challenged 
[18]. The tCho/tCre quotient is a historically estab-
lished diagnostic biomarker in brain tumours, which 
increases with progression of malignancy [20,23,24]. 
Concordant with this data we revealed that the tCho/
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Fig. 1. Global metabolic profiling of U87 glioma cells under adherent and suspension growth: Represen-
tative 1H NMR spectra of the intracellular metabolites of U87 glioma cells with annotated adenine (Ade), 
myo-inositol (myo), glycine (Gly), phosphocholine (PC), glycerophosphocholine (GPC), free choline (fCho), 
total choline (tCho = fCho + PC + GPC), total creatine (tCre), glutathione (GSH), glutamine (Gln), glutamate 
(Glu), N-acetylaspartylglutamate (NAAG), alanine (Ala), lactate (Lac), threonine (Thr) as well as valine/iso-
leucine (Val/Iso) plus internal concentration standard (STD). A) Relative quantification of phosphocholine, 
glycerophosphocholine, glycine, creatine, and myo-inositol revealed altered metabolism after transfer of 
U87 cells into neurosphere growth conditions: reduction of PC/GPC and Gly/tCho whereas Gly/myo and 
tCho/tCre ratios were increased (B), p = 0.05.
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tCre ratio is significantly increased in cells cultivated 
as neurospheres.
Glycine (Gly), a  currently intensively studied 
me tabolite with oncogenic potential, has been re port-
ed to be directly correlated with glioma malignancy 
[4]. Hypoxic glioma cells, which are known to contain 
a population of cells with high stem-like signature 
[11], are highly susceptible to glycine metabolism 
[13]. In addition, efforts using 1H-NMR-spectroscopy 
to grade brain tumour malignancy based on their 
cellular metabolism suggested glycine as a negative 
prognostic biomarker [5,17,22]. The Gly/tCre ratio is 
thought to be a  suitable parameter for grading of 
gliomas and for their distinction from brain metas-
tasis [14]. Interestingly, we did not notice differenc-
es in Gly/tCre between the two growth conditions. 
Therefore, we performed co-analyses with addi-
tional metabolites, including myo-inositol (myo) – 
a  metabolite reported to be reduced in high-grade 
as compared to low-grade brain tumours [3,19]. 
We could detect that the Gly/myo ratio, reported to 
be a valid marker for high-grade gliomas including 
GBM [22], is increased in suspension cells, indicating 
either the increase of Gly or the reduction of myo 
in neurospheres, as compared to adherent cells. 
An important route for the synthesis of glycine 
involves the degradation of choline [28]. We there-
fore sought to compare their relative concentrations 
in the two culture conditions and found the Gly/tCho 
ratio significantly diminished (about 75% decrease) 
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in neurosphere cells. The reduction of Gly/tCho could 
potentially be due to elevated concentrations of 
tCho in stem-like neurospheres, as increased tCho 
is an accepted marker for high-grade brain tumour 
malignancy [27].
Conclusions
In summary, we conclude that switching the cell 
culture conditions for U87 cells effectively alters their 
cellular metabolism, influencing a variety of metabo-
lites with reported importance in glioma and glioma 
stem cell progression. Cells propagated in suspen-
sion and adherent growth can dramatically alter their 
cellular proliferation and apoptosis rate due to alter-
ations in environmental stimuli. We confirm increased 
apoptosis in U87 neurosphere cells compared to cells 
grown as a monolayer. We cannot preclude, that the 
described metabolic differences might, at least par-
tially, be due to the increased cell death.
Therefore, particular caution has to be used 
interpreting the results of studies on cancer metabo-
lism in the context of the in vitro model. As reported 
here, substantial variations in intracellular levels of 
metabolites might be a consequence of different cul-
ture conditions, precluding the formulation of gener-
al conclusions.
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